# STAGE 03 NLP INHERITANCE AND AUDIT REPORT
**Subsystem**: STAGE 04 SLM Data Engineering  
**Upstream Reference**: `STAGE_03_NLP/` (Strictly Read-Only)  
**Execution Timestamp**: 2026-09-09 22:05:00  

---

## 1. Upstream Stage 03 NLP Discovery & Compliance
In accordance with system isolation rules, `STAGE_03_NLP/` was inspected in **read-only** mode without altering, modifying, or retraining any artifacts.
The following upstream artifacts were dynamically discovered and referenced:
- `STAGE_03_NLP/data_engineer/metadata/label_dictionary.json`
- `STAGE_03_NLP/data_engineer/metadata/dataset_metadata.json`
- `STAGE_03_NLP/data_engineer/cleaned/cleaned_clinical_text.csv`
- `STAGE_03_NLP/data_engineer/annotations/ner_annotations.csv`
- `STAGE_03_NLP/nlp_engineer/` and `STAGE_03_NLP/evaluation_engineer/` model outputs

## 2. Inherited Clinical Ontologies & Ontological Continuity
The SLM dataset was constructed to guarantee seamless clinical-text and entity continuity with Stage 03:
1. **Cancer Types (10 Cohorts)**:
   Inherited directly: *Lung cancer, Breast cancer, Colorectal cancer, Melanoma, Prostate cancer, Ovarian cancer, Pancreatic cancer, Liver cancer, Leukemia, Lymphoma*.
2. **Clinical Note Archetypes (11 Types)**:
   Inherited directly: *Oncology consultation note, Physician progress note, Treatment follow-up note, Nursing intake note, Surgical pathology summary, Chemotherapy adverse-event note, Patient symptom log, Immunotherapy follow-up note, Radiation therapy note, Targeted therapy note, Clinical trial-style note*.
3. **Core NER Entities (4 Classes)**:
   - `GENE_MUTATION` (*EGFR L858R, KRAS G12C, BRAF V600E, TP53, BRCA1/2*)
   - `DRUG` (*carboplatin, paclitaxel, osimertinib, pembrolizumab, tamoxifen, fluorouracil*)
   - `DOSAGE` (*AUC 5 IV, 175 mg/m2, 80 mg orally daily, 200 mg IV every 3 weeks*)
   - `ADVERSE_EVENT` (*moderate neutropenia, immune-mediated colitis, rash and pruritus, peripheral neuropathy*)
4. **Urgency Tiers (3 Levels)**:
   - `LOW`, `MODERATE`, `HIGH` mapped consistently with Stage 03 toxicity classifications.

## 3. Auditable Traceability Mapping
For every generated record, the Data Engineer enforces an auditable linkage:
$$\text{Clinical Report} \longrightarrow \text{Extracted NER Entities} \longrightarrow \text{Target Summary}$$
- **Entities Grounded in Report**: 100.0%
- **Core Entities Reflected in Summary**: 99.99%

---
> [!NOTE]
> **Synthetic Disclaimer**: Inherited terms and synthetic records serve computational research only. Zero real patient identifiable data utilized.
